| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation.
|
N Engl J Med
|
2014
|
4.00
|
|
2
|
miR-15a and miR-16-1 down-regulation in pituitary adenomas.
|
J Cell Physiol
|
2005
|
1.93
|
|
3
|
RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease.
|
Surgery
|
2002
|
1.49
|
|
4
|
Differentiated thyroid cancers 11-20 mm in diameter have clinical and histopathologic characteristics suggesting higher aggressiveness than those < or =10 mm.
|
Thyroid
|
2008
|
1.47
|
|
5
|
Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region.
|
Endocrine
|
2015
|
1.45
|
|
6
|
Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
|
Thyroid
|
2005
|
1.39
|
|
7
|
Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas.
|
J Cell Physiol
|
2007
|
1.37
|
|
8
|
Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome.
|
J Clin Endocrinol Metab
|
2006
|
1.15
|
|
9
|
Occurrence of pituitary dysfunction following traumatic brain injury.
|
J Neurotrauma
|
2004
|
1.10
|
|
10
|
Hypopituitarism after traumatic brain injury.
|
Eur J Endocrinol
|
2005
|
1.08
|
|
11
|
Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto's thyroiditis.
|
PLoS Pathog
|
2012
|
1.06
|
|
12
|
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.
|
Eur J Endocrinol
|
2010
|
1.04
|
|
13
|
Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
|
J Clin Endocrinol Metab
|
2012
|
1.01
|
|
14
|
Anterior pituitary function may predict functional and cognitive outcome in patients with traumatic brain injury undergoing rehabilitation.
|
J Neurotrauma
|
2007
|
1.00
|
|
15
|
Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
|
Thyroid
|
2005
|
0.97
|
|
16
|
Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients.
|
Endocr Relat Cancer
|
2012
|
0.96
|
|
17
|
Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone-releasing hormone.
|
Neuroendocrinology
|
2003
|
0.94
|
|
18
|
Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy.
|
World J Gastroenterol
|
2005
|
0.94
|
|
19
|
A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization.
|
Hum Mutat
|
2010
|
0.93
|
|
20
|
mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
|
Endocr Relat Cancer
|
2013
|
0.91
|
|
21
|
Levels of p27 sensitize to dual PI3K/mTOR inhibition.
|
Mol Cancer Ther
|
2011
|
0.88
|
|
22
|
Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review.
|
J Clin Endocrinol Metab
|
2015
|
0.88
|
|
23
|
miR-26a plays an important role in cell cycle regulation in ACTH-secreting pituitary adenomas by modulating protein kinase Cδ.
|
Endocrinology
|
2013
|
0.88
|
|
24
|
Runx2 mRNA expression in the tissue, serum, and circulating non-hematopoietic cells of patients with thyroid cancer.
|
J Clin Endocrinol Metab
|
2012
|
0.87
|
|
25
|
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer.
|
Thyroid
|
2014
|
0.87
|
|
26
|
Molecular basis of pharmacological therapy in Cushing's disease.
|
Endocrine
|
2013
|
0.86
|
|
27
|
Predictors of pituitary dysfunction in patients surviving ischemic stroke.
|
J Clin Endocrinol Metab
|
2010
|
0.84
|
|
28
|
Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli.
|
Endocrinology
|
2010
|
0.83
|
|
29
|
Corticotropin releasing hormone: a diagnostic marker for behavioral and reproductive disorders?
|
Front Biosci
|
2007
|
0.83
|
|
30
|
Protein kinase C: a putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro.
|
Endocrinology
|
2012
|
0.83
|
|
31
|
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression.
|
J Clin Endocrinol Metab
|
2012
|
0.82
|
|
32
|
Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro.
|
Endocrinology
|
2006
|
0.82
|
|
33
|
Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
|
Endocrine
|
2014
|
0.82
|
|
34
|
Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
|
Pituitary
|
2013
|
0.81
|
|
35
|
Systemic illness.
|
Pituitary
|
2008
|
0.80
|
|
36
|
Evidence for integrity of the growth hormone/insulin-like growth factor-1 axis in patients with severe head trauma during rehabilitation.
|
Metabolism
|
2002
|
0.80
|
|
37
|
Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function.
|
J Endocrinol
|
2013
|
0.80
|
|
38
|
Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature.
|
Endocrine
|
2014
|
0.79
|
|
39
|
Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy.
|
Bone
|
2013
|
0.79
|
|
40
|
Utilization of luminescent technology to develop a kinase assay: Cdk4 as a model system.
|
J Pharm Biomed Anal
|
2005
|
0.79
|
|
41
|
Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors.
|
Endocr Relat Cancer
|
2011
|
0.79
|
|
42
|
Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines.
|
J Cell Physiol
|
2007
|
0.77
|
|
43
|
Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
|
Metabolism
|
2005
|
0.77
|
|
44
|
Real-world study of everolimus in advanced progressive neuroendocrine tumors.
|
Oncologist
|
2015
|
0.76
|
|
45
|
Magmas overexpression inhibits staurosporine induced apoptosis in rat pituitary adenoma cell lines.
|
PLoS One
|
2013
|
0.76
|
|
46
|
Ovarian tumors secreting insulin.
|
Endocrine
|
2015
|
0.75
|
|
47
|
Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.
|
Endocrine
|
2013
|
0.75
|